Inventor wants to "Reboot" the Clinical Trials Industry
Remote Controlled Rx Dispenser
Clinical Trial Pharmacy
Home Based Clinical Trials
SAN DIEGO, CALIFORNIA, UNITED STATES, October 2, 2018 /EINPresswire.com/ -- Real Time Touch' inventor Linden hopes to improve the Clinical Trials industry with his new Remote Controlled Medication Dispenser and Telemedicine technology.
Remote Rx is Real Time Touch’s medication adherence dispenser envisioned with advanced IoT hardware, cloud and sensor capabilities. It’s backed by Linden’s patent and pending patents. Medical industry insiders who previewed plans have applauded the Remote Rx potential. View the Real Time Touch website for product and partner contact information: https://www.realtimetouch.com. “We’re aiming for a dramatic acceleration of Clinical Trial efficiency and effectiveness”, said Linden.
The advanced Remote Rx design is envisioned to include multi-level user/caregiver alerts, AI coaching, voice activation, voice/gesture recognition, biomarkers, highest-grade HIPAA-compliant security, AR and Augmented Virtual Reality (AVR). Test medications will be released by the clinical trial clinician while video conferencing with the trial patients in their homes. The Remote Rx dispenser will also help seniors stay independent longer, reduce hospital readmissions and remotely control the release of opioids.
The new Clinical Trials “reboot” initiative revealed additional projected product features: Clinical trial medication adherence will be monitored in real-time and combined with vitals data for faster results, effectiveness, scientific research and monitoring patient well-being.
When applied and approved by the FDA, clinical trial patients' test medications (pro-packs, pouches, patches, injectables, etc.) will be remotely released, verified and recorded via RTT’s exclusive home-based IoMT-locked dispensers while video visiting with their clinicians and/or via AI assist, or automatic release.
Clinical trial sponsors, advisors, doctors, nurses, caregivers and pharmacists can have varying levels of access to key data on demand in real-time or scheduled intervals. Linden noted that “the potential savings to big pharma will likely dwarf any associated investment.”
Potential partners and investors should contact Real Time Touch for their PartnerDeck information packet (PDF): https://www.realtimetouch.com/remoterx/
According to Linden, Remote Rx “reboot” for clinical trials could ”multiply the capacity of the limited number of clinicians, it’s integrated AR and AI would drive broad efficiency improvements with associated returns incentivizing more and more effective trials, it could speed the release of new critical drugs. Linden's vision also seeks to "reduce patient transportation issues, expand geographical boundaries, increase rare disease group sizes, reduce language barriers, enable mentoring/trending/alarms of vitals, provide face-to-face engagement/coaching, and enable live face/voice bidirectional patient-centered recognition and/or AI-assisted biometric patient ID. “
CRAIG LINDEN
REAL TIME TOUCH
1-619-3013555
email us here
Visit us on social media:
Twitter
LinkedIn
Real Time Touch Digital Health Introduction
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.
